MICA/B antibodies and methods of use
AssigneeCullinan Mica Corporation
InventorsNeil Gibson, Justin Chapman, Xin Du
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies that specifically bind to MICA/B having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions disclosed herein, as well as methods and uses thereof.
Claims12
A monoclonal antibody or an antigen-binding fragment thereof that specifically binds to a MICA protein, a MICB protein, or both MICA and MICB proteins, comprising a light chain complementarity determining region 1 (CDR1) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 1, a light chain complementarity determining region 2 (CDR2) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 2, a light chain complementarity determining region 3 (CDR3) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 3, a heavy chain complementarity determining region 1 (CDR1) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 4, a heavy chain complementarity determining region 2 (CDR2) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 5, and a heavy chain complementarity determining region 3 (CDR3) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 6.
A method of treating cancer in an individual in need thereof, comprising administering to the individual an effective amount of a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to a MICA protein, a MICB protein, or both MICA and MICB proteins, comprising a light chain complementarity determining region 1 (CDR1) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 1, a light chain complementarity determining region 2 (CDR2) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 2, a light chain complementarity determining region 3 (CDR3) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 3, a heavy chain complementarity determining region 1 (CDR1) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 4, a heavy chain complementarity determining region 2 (CDR2) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 5, and a heavy chain complementarity determining region 3 (CDR3) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 6.
A method of reducing level of soluble MICA protein, soluble MICB protein, or both in an individual in need thereof, comprising administering to the individual an effective amount of a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to a MICA protein, a MICB protein, or both MICA and MICB proteins, comprising of a light chain complementarity determining region 1 (CDR1) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 1, a light chain complementarity determining region 2 (CDR2) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 2, and a light chain complementarity determining region 3 (CDR3) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 3, a heavy chain complementarity determining region 1 (CDR1) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 4, a heavy chain complementarity determining region 2 (CDR2) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 5, and a heavy chain complementarity determining region 3 (CDR3) sequence comprising the amino acid sequence set forth as SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.